CaseBioscience has launched CaseCryo CTG DMSO, a next-generation cryopreservation solution developed to support clinical cell therapy development, at Advanced Therapies Week (ATW) 2026.
The company will also introduce CaseStor HSS Hypothermic Storage Solution, designed for the controlled hypothermic storage of cells and tissues.
CaseCryo CTG DMSO and CaseStor HSS are manufactured under cGMP-aligned, ISO 13485:2016–certified quality systems at CaseBioscience’s FDA-registered facility, applying ART-inspired quality principles.
Drug Master Files (DMFs) have been filed for both products to support clinical development and regulatory alignment.
CaseCryo CTG DMSO is engineered with a systems-level view of cryopreservation as an end-to-end process, supporting sustained cell survival, functional performance, and manufacturing consistency beyond immediate post-thaw viability. CaseStor HSS provides a dedicated solution for hypothermic storage of cells and tissues, supporting diverse cell therapy workflows.
Evaluations of these new biopreservation solutions highlight their potential to support long-term cell health and performance. CaseStor HSS improves post-storage expansion of hPSCs, T cells, and MSCs, while CaseCryo CTG DMSO enhances long-term recovery and expansion of T cells and hPSCs compared with leading commercially available solutions. These findings reflect CaseBioscience’s systems-level approach to biopreservation, designed to go beyond immediate viability and support sustained functional outcomes throughout cell therapy development and manufacturing workflows.
“Cryopreservation and hypothermic storage are critical to enabling cell and tissue therapies,” said Kevin Flynn, chief scientific officer at CaseBioscience.
“With CaseCryo CTG DMSO and CaseStor HSS, we’re providing solutions built for clinical applications that prioritize long-term cell performance, quality, and regulatory rigour.”
CaseBioscience’s research was recently highlighted at the ISSCR PSC-Derived Therapies Symposium, where the company presented a poster, “An AI-assisted literature screening approach identifies potential DMSO-free cryoprotectants for optimal preservation of human Pluripotent- and Neural- Stem Cells.” This work underscores the company’s ongoing commitment to next-generation biopreservation solutions that support emerging cell therapy modalities.